FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients were required to discontinue their existing ACE inhibitor or ARB therapy and enter a sequential single-blind run-in period during which they received treatment with enalapril 10 mg twice daily, followed by single-blind treatment with Entresto 100 mg twice daily, increasing to 200 mg twice daily (see section 4.8 for discontinuations during this period).
Slovenian: Bolniki so morali prekiniti dotedanje zdravljenje z zaviralci ACE oziroma zaviralci angiotenzinskih receptorjev in se vključiti v obdobje enojno slepega uvajalnega zdravljenja, v katerem so najprej prejemali enalapril 10 mg dvakrat na dan, nato enojno slepo zdravljenje z zdravilom Entresto v odmerku 100 mg dvakrat na dan, nato pa so jim odmerek zvišali na 200 mg dvakrat na dan (za podatke o prekinitvah zdravljenja v tem obdobju glejte poglavje 4.8).
English: The most commonly reported adverse reactions during treatment with Entresto were hypotension, hyperkalaemia and renal impairment (see section 4.4).
Slovenian: Neželeni učinki, o katerih so med zdravljenjem z zdravilom Entresto najbolj pogosto poročali, so bili hipotenzija, hiperkaliemija in okvara ledvic (glejte poglavje 4.4).
English: 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 168 film-coated tablets 196 film-coated tablets
Slovenian: 14 filmsko obloženih tablet 20 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 168 filmsko obloženih tablet 196 filmsko obloženih tablet
English: • Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Slovenian: • Zdravilo Entresto vsebuje valsartan, zato se ga ne sme odmerjati sočasno z drugim zdravilom, ki vsebuje zaviralec angiotenzinskih receptorjev (glejte poglavji 4.2 in 4.5).
English: 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 196 film-coated tablets
Slovenian: 14 filmsko obloženih tablet 20 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 196 filmsko obloženih tablet
English: If any of the above applies to you, tell your doctor or pharmacist before you take Entresto.
Slovenian: Če karkoli od navedenega velja za vas, povejte svojemu zdravniku ali farmacevtu, preden začnete jemati zdravilo Entresto.
English: How to take Entresto
Slovenian: Kako jemati zdravilo Entresto
English: In PARADIGM-HF, renal impairment was reported in 10.1% of Entresto-treated patients and 11.5% of enalapril-treated patients.
Slovenian: V študiji PARADIGM-HF so o okvari ledvic poročali pri 10,1 % bolnikov, ki so prejemali zdravilo Entresto, in pri 11,5 % tistih bolnikov, ki so prejemali enalapril.
English: In the PARADIGM-HF study, Entresto decreased plasma NT-proBNP and increased plasma BNP and urine cGMP compared with enalapril.
Slovenian: V študiji PARADIGM-HF je zdravilo Entresto znižalo koncentracijo NT-proBNP v plazmi in zvišalo koncentraciji BNP v plazmi ter cGMP v urinu v primerjavi z uporabo enalaprila.
English: It is teratogenic based on a low incidence of foetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an Entresto dose of ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day.
Slovenian: Zdravilo je teratogeno glede na podatke o majhni pogostnosti hidrocefalije pri plodu ob odmerkih, ki so toksični za mater, kar so opažali pri kuncih pri odmerku zdravila Entresto ≥4,9 mg sakubitrila/5,1 mg valsartana /kg/dan.
English: If any of the above applies to you, tell your doctor, pharmacist or nurse before you take Entresto.
Slovenian: Če karkoli od navedenega velja za vas, povejte svojemu zdravniku, farmacevtu ali medicinski sestri, preden začnete jemati zdravilo Entresto.
English: More patients who were naïve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to <10 mg enalapril/day) were able to achieve and maintain Entresto 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%).
Slovenian: Med bolniki, ki še niso prejemali zaviralcev ACE ali angiotenzinskih receptorjev ali pa so jih prejemali v nizkih odmerkih (enakovrednih <10 mg enalaprila na dan), jih je več doseglo in vztrajalo pri prejemanju odmerka 200 mg zdravila Entresto, če so jim odmerke zviševali v obdobju 6 tednov (84,8 %), kot če so jim odmerke zviševali v obdobju 3 tednov (73,6 %).
English: Co-administration of nitroglycerin and Entresto was associated with a treatment difference of 5 bpm in heart rate compared to the administration of nitroglycerine alone.
Slovenian: Sočasna uporaba nitroglicerina in zdravila Entresto je bila povezana z znižanjem srčne frekvence za 5 utripov na minuto v primerjavi z odmerjanjem samo nitroglicerina.
English: If treatment with Entresto is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Entresto (see sections 4.2, 4.3 and 4.5).
Slovenian: Če bolnik prekine zdravljenje z zdravilom Entresto, se zdravljenja z zaviralcem ACE ne sme začeti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zdravila Entresto (glejte poglavja 4.2, 4.3 in 4.5).
English: The adverse embryofoetal effects of Entresto are attributed to the angiotensin receptor antagonist activity (see section 4.6).
Slovenian: Neželene učinke zdravila Entresto na zarodek oziroma plod je mogoče pripisati njegovi aktivnosti, ki jo ima kot antagonist angiotenzinskih receptorjev (glejte poglavje 4.6).
English: Cardiovascular abnormalities (mainly cardiomegaly) were observed in rabbit foetuses at a maternally non-toxic dose (1.46 mg sacubitril/1.54 mg valsartan/kg/day).
Slovenian: (večinoma kardiomegalijo) pri odmerkih, ki niso bili toksični za mater (1,46 mg sakubitrila/1,54 mg valsartana/kg/dan).
English: What Entresto contains
Slovenian: Kaj vsebuje zdravilo Entresto
English: Pack sizes: 14, 20, 28, 56, 168 or 196 film-coated tablets and multipacks containing 168 (3x56) or 196 (7x28) film-coated tablets.
Slovenian: Velikosti pakiranj: 14, 20, 28, 56, 168 ali 196 filmsko obloženih tablet ali skupno pakiranje, ki vsebuje 168 (3x56) ali 196 (7x28) filmsko obloženih tablet.
English: Approximate tablet dimensions 13.1 mm x 5.2 mm Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Slovenian: Tablete so velike približno 13,1 mm x 5,2 mm. Entresto 97 mg/103 mg filmsko obložene tablete so svetlo rožnate ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "L11" na drugi.
English: Following oral administration, Entresto dissociates into valsartan and the prodrug sacubitril.
Slovenian: Zdravilo Entresto po peroralnem odmerjanju disociira v valsartan in sakubitril, ki je predzdravilo.
English: Entresto is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or with hereditary or idiopathic angioedema (see section 4.3).
Slovenian: Uporaba zdravila Entresto je kontraindicirana pri bolnikih z anamnezo angioedema zaradi predhodnega zdravljenja z zaviralcem ACE ali zaviralcem angiotenzinskih receptorjev ali z dednim ali idiopatskim angioedemom (glejte poglavje 4.3).
English: In a 21-day study in HFrEF patients, Entresto significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1 compared to baseline.
Slovenian: V 21-dnevni študiji pri bolnikih z zmanjšanim iztisnim deležem je uporaba zdravila Entresto statistično značilno zvišala koncentraciji ANP in cGMP v urinu in koncentracijo cGMP v plazmi ter znižala plazemske koncentracije NT-proBNP, aldosterona in endotelina-1 v primerjavi z izhodiščnimi vrednostmi.
English: Entresto 97 mg/103 mg film-coated tablets
Slovenian: Entresto 97 mg/103 mg filmsko obložene tablete
English: If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).
Slovenian: Če ste do zdaj jemali katerega od zaviralcev ACE, morate po zaužitju zadnjega odmerka počakati 36 ur, preden začnete jemati zdravilo Entresto (glejte pod naslovom "Druga zdravila in zdravilo Entresto").
English: Interactions between Entresto and lithium have not been investigated.
Slovenian: Medsebojnega delovanja med zdravilom Entresto in litijem niso raziskovali, zato uporaba te kombinacije ni priporočena.
English: The valsartan contained within Entresto is more bioavailable than the valsartan in other marketed tablet formulations; 26 mg, 51 mg, and 103 mg of valsartan in Entresto is equivalent to 40 mg, 80 mg and 160 mg of valsartan in other marketed tablet formulations, respectively.
Slovenian: 26 mg, 51 mg oziroma 103 mg valsartana v zdravilu Entresto ustreza 40 mg, 80 mg oziroma 160 mg valsartana v drugih formulacijah tablet, ki so dostopne na trgu.
English: ACE inhibitor therapy must not be started until 36 hours after the last dose of Entresto (see sections 4.2 and 4.3).
Slovenian: Zdravljenja z zaviralcem ACE se ne sme začeti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zdravila Entresto (glejte poglavji 4.2 in 4.3).
English: How to store Entresto
Slovenian: Shranjevanje zdravila Entresto
English: Entresto 49 mg/51 mg film-coated tablets
Slovenian: Entresto 49 mg/51 mg filmsko obložene tablete
English: If you stop taking Entresto, wait 36 hours after taking your last dose of Entresto before starting an ACE inhibitor.
Slovenian: Če prenehate jemati zdravilo Entresto, morate po zaužitju zadnjega odmerka zdravila Entresto počakati 36 ur, preden začnete jemati zaviralec ACE.
English: Entresto 24 mg/26 mg film-coated tablets
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete Entresto 49 mg/51 mg filmsko obložene tablete Entresto 97 mg/103 mg filmsko obložene tablete
English: Animal studies with Entresto have shown reproductive toxicity (see section 5.3).
Slovenian: Študije zdravila Entresto na živalih so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
English: Entresto exhibits the mechanism of action of an angiotensin receptor neprilysin inhibitor by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan.
Slovenian: Mehanizem delovanja zdravila Entresto je zaviranje angiotenzinskih receptorjev in neprilizina, in sicer s substanco LBQ657, ki je aktivni metabolit predzdravila sakubitrila, zavira neprilizin (nevtralno endopeptidazo, NEP), hkrati pa z valsartanom zavira tudi receptor za angiotenzin II tipa 1 (AT1).
English: A single dose of Entresto 583 mg sacubitril/617 mg valsartan and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) were studied in healthy volunteers and were well tolerated.
Slovenian: Pri zdravih prostovoljcih so proučevali odmerjanje enkratnega odmerka zdravila Entresto s 583 mg sakubitrila in 617 mg valsartana ter večkratnih odmerkov po 437 mg sakubitrila in 463 mg valsartana (v 14 dneh), kar so preiskovanci dobro prenašali.
English: Pack sizes: 14, 20, 28, 56 or 196 film-coated tablets and multipacks containing 196 (7x28) film-coated tablets.
Slovenian: Velikosti pakiranj: 14, 20, 28, 56 ali 196 filmsko obloženih tablet ali skupno pakiranje, ki vsebuje 196 (7x28) filmsko obloženih tablet.
English: Following twice daily dosing of Entresto, steady-state levels of sacubitril, LBQ657 and valsartan are reached in three days.
Slovenian: Pri odmerjanju zdravila Entresto dvakrat na dan dosežejo sakubitril, substanca LBQ657 in valsartan stanje dinamičnega ravnovesja v treh dneh.
English: The complementary cardiovascular benefits of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan.
Slovenian: Komplementarne srčno-žilne koristi zdravila Entresto pri bolnikih s srčnim popuščanjem je mogoče pripisati delovanju substance LBQ657 (ta povečuje obseg delovanja peptidov, ki jih sicer razgrajuje neprilizin, kot so natriuretični peptidi) ter hkratnemu delovanju valsartana, ki zavira delovanje angiotenzina II.
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete Entresto 49 mg/51 mg filmsko obložene tablete Entresto 97 mg/103 mg filmsko obložene tablete sakubitril/valsartan
English: Therefore, monitoring of renal function is recommended when initiating or modifying treatment in patients on Entresto who are taking NSAIDs concomitantly (see section 4.4).
Slovenian: Pri bolnikih, ki sočasno prejemajo zdravilo Entresto in nesteroidna protivnetna zdravila, je zato priporočeno spremljanje ledvične funkcije v času uvedbe ali spreminjanja zdravljenja (glejte poglavje 4.4).
English: If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Entresto (see “Do not take Entresto”).
Slovenian: Če ste do zdaj jemali katerega od zaviralcev ACE, morate po zaužitju zadnjega odmerka počakati 36 ur, preden začnete jemati zdravilo Entresto (glejte pod naslovom " Ne jemljite zdravila Entresto").
English: Caution should be exercised when co-administering Entresto with statins.
Slovenian: Pri sočasni uporabi zdravila Entresto s statini je potrebna previdnost.
English: Entresto is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).
Slovenian: Pri bolnikih s hudo okvaro jeter, biliarno cirozo ali holestazo (Child-Pugh stopnje C) je uporaba zdravila Entresto kontraindicirana (glejte poglavje 4.3).
English: No clinically relevant drug-drug interaction was observed when simvastatin and Entresto were coadministered.
Slovenian: Pri sočasni uporabi simvastatina in zdravila Entresto niso opažali nobenih klinično pomembnih interakcij.
English: What Entresto looks like and contents of the pack Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete so vijoličasto bele ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "LZ" na drugi.
English: Entresto may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis.
Slovenian: Pri bolnikih z obojestransko ali enostransko stenozo ledvične arterije lahko uporaba zdravila Entresto zviša koncentracije sečnine v krvi in kreatinina v serumu.
English: Hypotension is the most likely symptom of overdose due to the blood pressure lowering effects of Entresto.
Slovenian: Glede na to, da zdravilo Entresto znižuje krvni tlak, bi bil najbolj verjeten simptom prevelikega odmerjanja lahko hipotenzija.
English: Addition of a single dose of sildenafil to Entresto at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of Entresto alone.
Slovenian: Zaviralci fosfodiesteraze tipa 5 (PDE5), vključno s sildenafilom Pri bolnikih, ki so imeli hipertenzijo in so dosegli stanje dinamičnega ravnovesja pri odmerjanju zdravila Entresto, je dodatek enkratnega odmerka sildenafila povzročil bistveno večje znižanje krvnega tlaka kot odmerjanje samo zdravila Entresto.
English: Entresto should not be co-administered with an ACE inhibitor or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, it must not be started for at least 36 hours after discontinuing ACE inhibitor therapy (see sections 4.3, 4.4 and 4.5).
Slovenian: Ker pri sočasni uporabi z zaviralcem ACE obstaja tveganje za angioedem, se ga ne sme uvesti prej kot po preteku 36 ur od prekinitve zdravljenja z zaviralcem ACE (glejte poglavja 4.3, 4.4 in 4.5).
English: • if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see “Do not take Entresto”).
Slovenian: • če se zdravite z zaviralcem angiotenzinskih receptorjev ali z aliskirenom (glejte pod naslovom
English: Angioedema has been reported in patients treated with Entresto.
Slovenian: Pri bolnikih, ki so prejemali zdravilo Entresto, so poročali o angioedemu.
English: The average daily dose of furosemide was unchanged from baseline until the end of the PARADIGM-HF study in patients treated with Entresto.
Slovenian: V študiji PARADIGM-HF so bolniki, ki so prejemali zdravilo Entresto, prejemali furosemid v nespremenjenem dnevnem odmerku od izhodišča do konca študije.
English: No dose adjustment is required when administering Entresto to patients with mild hepatic impairment (Child-Pugh A classification).
Slovenian: Pri odmerjanju zdravila Entresto bolnikom z blago okvaro jeter (Child-Pugh stopnje A) prilagajanje odmerkov ni potrebno.
English: Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Slovenian: Interakcije, zaradi katerih sočasna uporaba ni priporočena Zdravilo Entresto vsebuje valsartan, zato se ga ne sme odmerjati sočasno z drugim zdravilom, ki vsebuje zaviralec angiotenzinskih receptorjev (glejte poglavje 4.4).
English: The combination of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.3 and 4.5).
Slovenian: Kombinacija zdravila Entresto z zdravili, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo in pri bolnikih z okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije <60 ml/min/1,73 m2) (glejte poglavji 4.3 in 4.5).
English: Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Slovenian: Zdravila Entresto se ne sme odmerjati prej kot po preteku 36 ur od prekinitve zdravljenja z zaviralcem ACE.
English: The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Slovenian: Sočasna uporaba zdravila Entresto z zdravili, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo in pri bolnikih z okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije <60 ml/min/1,73 m2) (glejte poglavje 4.3).
English: Entresto 97 mg/103 mg tablets sacubitril/valsartan
Slovenian: Entresto 97 mg/103 mg tablete sakubitril/valsartan
English: Monitoring of serum potassium is recommended if Entresto is co-administered with these agents (see section 4.4).
Slovenian: Pri sočasni uporabi zdravila Entresto in navedenih zdravil je priporočeno spremljanje vrednosti kalija v serumu (glejte poglavje 4.4).
English: Entresto may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins.
Slovenian: Substrati prenašalcev OATP1B1 in OATP1B3, na primer statini Podatki in vitro kažejo, da sakubitril zavira prenašalca OATP1B1 in OATP1B3, zato bi zdravilo Entresto lahko povečalo sistemsko izpostavljenost substratom OATP1B1 in OATP1B3, kot so statini.
English: BNP is not a suitable biomarker of heart failure in patients treated with Entresto because it is a neprilysin substrate (see section 5.1).
Slovenian: Natriuretični peptid tipa B (možganski natriuretični peptid, BNP) Pri bolnikih, ki prejemajo zdravilo Entresto, možganski natriuretični peptid ni primeren biološki označevalec srčnega popuščanja, saj je substrat neprilizina (glejte poglavje 5.1).
English: Entresto 24 mg/26 mg tablets sacubitril/valsartan
Slovenian: Entresto 24mg/26 mg tablete sakubitril/valsartan
English: Entresto 49 mg/51 mg tablets sacubitril/valsartan
Slovenian: Entresto 49 mg/51 mg tablete sakubitril/valsartan
English: Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Slovenian: Entresto 97 mg/103 mg filmsko obložene tablete sakubitril/valsartan
English: Entresto 24 mg/26 mg film-coated tablets sacubitril/valsartan
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete sakubitril/valsartan
English: Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Slovenian: Zdravljenja z zdravilom Entresto se ne sme začeti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
English: Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Slovenian: Iz tega razloga lahko sočasna uporaba zdravila Entresto z zaviralci OATP1B1, OATP1B3, OAT3 (kot sta rifampicin in ciklosporin), OAT1 (kot sta tenofovir in cidofovir) ali MRP2 (kot je ritonavir) poveča sistemsko izpostavljenost substanci LBQ657 oziroma valsartanu.
English: Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Entresto 97 mg/103 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
English: Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Entresto 49 mg/51 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) rumeni železov oksid (E172)
English: Entresto must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy.
Slovenian: Zdravljenja z zdravilom Entresto se ne sme uvesti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
English: Entresto 49 mg/51 mg film-coated tablets sacubitril/valsartan
Slovenian: Entresto 49 mg/51 mg filmsko obložene tablete sakubitril/valsartan
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists.
Slovenian: Zdravila Entresto se ne sme odmerjati sočasno z zaviralcem ACE ali zaviralcem receptorjev angiotenzina II.
English: Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Entresto 24 mg/26 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
English: A similar effect on the heart rate may occur when Entresto is co-administered with sublingual, oral or transdermal nitrates.
Slovenian: Pri sočasni uporabi zdravila Entresto in sublingvalne, peroralne ali transdermalne oblike nitratov lahko pride do podobnih učinkov na srčno frekvenco.
English: Your doctor may check the amount of potassium in your blood at regular intervals during Entresto treatment.
Slovenian: V času zdravljenja z zdravilom Entresto vam bo zdravnik verjetno redno preverjal koncentracijo kalija v krvi.
English: Do not take Entresto with ACE inhibitors.
Slovenian: • zaviralcev ACE: zdravila Entresto ne smete jemati sočasno z zaviralci ACE.
English: Package leaflet: Information for the patient
Slovenian: Shranjevanje zdravila Entresto Vsebina pakiranja in dodatne informacije
English: No. at risk Entresto
Slovenian: Zdravilo Entresto
English: Do not use any Entresto pack that is damaged or shows signs of tampering.
Slovenian: Če opazite, da je ovojnina zdravila Entresto poškodovana ali da je bila že odprta, ne uporabljajte tega pakiranja.
English: The infusion lasts 2 hours.
Slovenian: Infundiranje traja dve uri.
English: Patients should also take vitamin D and calcium supplements.
Slovenian: Bolniki morajo jemati tudi vitamin D in kalcijeve dodatke.
English: This will normally bring the blood calcium level down to normal levels within a week.
Slovenian: Običajno se bo s tem raven kalcija v krvi v tednu dni znižala na normalno raven.